Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial

Journal:
The Lancet
Published:
Affiliations:
21
Authors:
92
Institutions Authors Share
University of Plymouth, United Kingdom (UK)
7.050000
0.23
Leeds Cancer Centre, LTHT, United Kingdom (UK)
4.050000
0.13
University Hospitals Plymouth NHS Trust, United Kingdom (UK)
2.050000
0.07
Comprehensive Cancer Center Finland (FICAN), Finland
1.050000
0.03
University of Southampton (Soton), United Kingdom (UK)
1.050000
0.03
Karolinska University Hospital, Sweden
1.050000
0.03
Oslo University Hospital (OUS), Norway
1.050000
0.03
Skåne University Hospital in Lund, SUS, Sweden
1.050000
0.03
UCL, United Kingdom (UK)
1.050000
0.03
St. Olavs Hospital (Trondheim University Hospital), NTNU, Norway
1.050000
0.03
Aarhus University Hospital, Denmark
1.050000
0.03
University of Exeter, United Kingdom (UK)
1.050000
0.03
The University of Nottingham (UoN), United Kingdom (UK)
1.050000
0.03
Linköping University Hospital, Sweden
1.050000
0.03
Zealand University Hospital, Denmark
1.050000
0.03
Odense University Hospital (OUH), Denmark
1.050000
0.03
Uppsala University (UU), Sweden
1.050000
0.03
Churchill Hospital, United Kingdom (UK)
1.050000
0.03
Sheffield Teaching Hospitals NHS Foundation Trust, United Kingdom (UK)
1.050000
0.03
AstraZeneca, United Kingdom (UK)
1.050000
0.03